News Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™ Staff June 25, 2022 Post Navigation Previous Jushi Holdings Inc. Amends and Refiles Q1 2022 Financial StatementsNext Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress™ 2022 and Provides AB-836 Clinical Update More Stories News Personal Data DATA BREACH ALERT: Edelson Lechtzin LLP Is Investigating Claims On Behalf Of Ascension Health Customers Whose Data May Have Been Compromised Staff December 22, 2024 Cancer Diagnostics Healthcare immunotherapy Mental Health News Art Bio Miami and The Global Passion Projects: Where Scientific Innovation, Creativity and Philanthropy Converge to Transform Lives Staff December 21, 2024 Apps Fitness News Daily Fit Notes Rolls Out Affordable Fitness Solutions for the Modern Lifestyle Staff December 21, 2024
